+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Brain & Spinal Cord Cancer Market by Tumor Type, Treatment, End-users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968082
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Brain & Spinal Cord Cancer Market grew from USD 3.77 billion in 2023 to USD 3.98 billion in 2024. It is expected to continue growing at a CAGR of 5.75%, reaching USD 5.59 billion by 2030.

Brain and spinal cord cancers are characterized by the abnormal growth of cells within the brain or spine, leading to critical medical conditions. The scope and definition encompass various benign and malignant tumors affecting these central nervous system components. The necessity for understanding this market lies in the high morbidity and mortality rates associated with these cancers, propelling the demand for innovative diagnostics and therapeutics. Application extends to pharmaceuticals, medical devices, and diagnostic tools designed to improve early detection, treatment, and patient quality of life. The end-use sectors primarily include hospitals, diagnostic centers, cancer treatment facilities, and research institutions.

Market insights indicate that the growth is significantly influenced by advances in precision medicine, rising government funding for cancer research, and the increasing prevalence of brain and spinal abnormalities globally. The emergence of novel therapies such as immunotherapy and targeted treatments is creating potential opportunities for stakeholders. Recommendations to seize these opportunities include investing in R&D to develop cutting-edge solutions, fostering partnerships with research institutions, and leveraging artificial intelligence for diagnostic accuracy.

However, the market growth is challenged by high treatment costs, stringent regulatory frameworks, and the complex nature of these cancers which makes treatment development arduous. Additionally, limited access to treatment in low-resource regions hampers global market expansion. Innovations in minimally invasive surgical techniques, personalized medicine, and non-invasive imaging technologies represent fertile areas for research and development. Businesses should focus on developing cost-effective therapies and improving access through digital platforms to enhance patient outreach.

The market is highly competitive and collaborative, driven by continuous technological advancements. Companies aiming to thrive should focus on aligning with government policies on healthcare expenditure, engaging in awareness programs, and creating strategic alliances to streamline drug development processes. A deeper understanding of patient needs and ongoing monitoring of competitive dynamics will further guide successful market navigation.

Understanding Market Dynamics in the Brain & Spinal Cord Cancer Market

The Brain & Spinal Cord Cancer Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of brain and spinal cord cancers globally
    • Increased investment in healthcare infrastructure with growing awareness about these conditions
    • Ongoing government initiatives aimed at cancer research and early detection
  • Market Restraints
    • High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer
  • Market Opportunities
    • Incorporation of AI and machine learning in diagnostic processes
    • Increasing preference for personalized medicine based on genetic profile
  • Market Challenges
    • Concerns associated with the complex nature of brain and spinal cord cancers

Exploring Porter’s Five Forces for the Brain & Spinal Cord Cancer Market

Porter’s Five Forces framework further strengthens the insights of the Brain & Spinal Cord Cancer Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Brain & Spinal Cord Cancer Market

External macro-environmental factors deeply influence the performance of the Brain & Spinal Cord Cancer Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Brain & Spinal Cord Cancer Market

The Brain & Spinal Cord Cancer Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Brain & Spinal Cord Cancer Market

The Brain & Spinal Cord Cancer Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Brain & Spinal Cord Cancer Market

The Brain & Spinal Cord Cancer Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain & Spinal Cord Cancer Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bayer AG, bluebird bio, Inc., Bristol Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Eisai Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc., Nektar Therapeutics, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shimadzu Corporation, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., and Y-mAbs Therapeutics A/S.

Market Segmentation & Coverage

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Tumor Type
    • Glioblastoma
    • Meningioma
    • Pituitary Tumors
  • Treatment
    • Diagnosis
      • Cerebral Arteriogram
      • CT Scan
      • EEG
      • Lumbar Puncture
      • Molecular Testing
      • MRI
      • PET-CT Scan
      • Tissue Sampling
    • Therapeutics
      • Chemotherapy
      • Immunotherapy
      • Radiation Therapy
      • Surgery
      • Targeted Therapy
  • End-users
    • Ambulatory Surgical Centers
    • Diagnostic Centers
    • Hospital & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of brain and spinal cord cancers globally
5.1.1.2. Increased investment in healthcare infrastructure with growing awareness about these conditions
5.1.1.3. Ongoing government initiatives aimed at cancer research and early detection
5.1.2. Restraints
5.1.2.1. High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer
5.1.3. Opportunities
5.1.3.1. Incorporation of AI and machine learning in diagnostic processes
5.1.3.2. Increasing preference for personalized medicine based on genetic profile
5.1.4. Challenges
5.1.4.1. Concerns associated with the complex nature of brain and spinal cord cancers
5.2. Market Segmentation Analysis
5.2.1. Treatment:
5.2.2. End-users:
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Brain & Spinal Cord Cancer Market, by Tumor Type
6.1. Introduction
6.2. Glioblastoma
6.3. Meningioma
6.4. Pituitary Tumors
7. Brain & Spinal Cord Cancer Market, by Treatment
7.1. Introduction
7.2. Diagnosis
7.2.1. Cerebral Arteriogram
7.2.2. CT Scan
7.2.3. EEG
7.2.4. Lumbar Puncture
7.2.5. Molecular Testing
7.2.6. MRI
7.2.7. PET-CT Scan
7.2.8. Tissue Sampling
7.3. Therapeutics
7.3.1. Chemotherapy
7.3.2. Immunotherapy
7.3.3. Radiation Therapy
7.3.4. Surgery
7.3.5. Targeted Therapy
8. Brain & Spinal Cord Cancer Market, by End-users
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Diagnostic Centers
8.4. Hospital & Clinics
9. Americas Brain & Spinal Cord Cancer Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Brain & Spinal Cord Cancer Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Brain & Spinal Cord Cancer Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Diakonos’ brain tumor vaccine receives FDA’s orphan drug designation
12.3.2. Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BRAIN & SPINAL CORD CANCER MARKET RESEARCH PROCESS
FIGURE 2. BRAIN & SPINAL CORD CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRAIN & SPINAL CORD CANCER MARKET DYNAMICS
TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CEREBRAL ARTERIOGRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EEG, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LUMBAR PUNCTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PET-CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TISSUE SAMPLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 49. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 52. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 53. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 76. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 79. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 80. CHINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 84. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 85. INDIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 89. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 92. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 94. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. JAPAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 99. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 104. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 109. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 114. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 115. SOUTH KOREA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 119. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. TAIWAN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 122. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 124. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 125. THAILAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 129. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 130. VIETNAM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 138. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 140. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 143. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 145. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 146. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 147. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 148. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 150. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 151. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 158. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 160. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 165. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 166. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 167. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 169. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 170. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 171. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 182. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 183. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 185. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 186. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 187. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 188. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 190. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 191. POLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 192. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 193. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 195. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 196. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 212. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 242. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 243. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Brain & Spinal Cord Cancer Market, which are profiled in this report, include:
  • Amgen Inc.
  • Bayer AG
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics A/S

Methodology

Loading
LOADING...

Table Information